During the past decade, Edward H Kaplan MD and Associates conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 15 clinical trials were completed, i.e. on average, 214.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Edward H Kaplan MD and Associates" #1 sponsor was "National Cancer Institute (NCI)" with 13 trials, followed by "Xiamen LP Pharmaceutical Co., Ltd" with 2 trials sponsored, "Adaptive Biotechnologies" with 1 trials sponsored, "Alliance for Clinical Trials in Oncology" with 1 trials sponsored and "Celgene" with 1 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Edward H Kaplan MD and Associates" #1 collaborator was "Cancer and Leukemia Group B" with 4 trials as a collaborator, "NCIC Clinical Trials Group" with 4 trials as a collaborator, "National Cancer Institute (NCI)" with 3 trials as a collaborator, "North Central Cancer Treatment Group" with 3 trials as a collaborator and "SWOG Cancer Research Network" with 3 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Edward H Kaplan MD and Associates" are "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome" (2 trials), "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11" (2 trials), "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11" (2 trials), "Adult Acute Myeloid Leukemia in Remission" (2 trials) and "Alkylating Agent-Related Acute Myeloid Leukemia" (2 trials). Many other conditions were trialed in "Edward H Kaplan MD and Associates" in a lesser frequency.

Most popular intervention types in "Edward H Kaplan MD and Associates" are "Drug" (25 trials), "Other" (9 trials), "Biological" (8 trials), "Radiation" (3 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (8 trials), "Bevacizumab" (4 trials), "leucovorin calcium" (4 trials), "Quality-of-Life Assessment" (3 trials) and "fluorouracil" (3 trials). Other intervention names were less common.

The vast majority of trials in "Edward H Kaplan MD and Associates" are 25 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Edward H Kaplan MD and Associates". undefined are not yet recruiting, 4 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Edward H Kaplan MD and Associates, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Edward H Kaplan MD and Associates, 2 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".